Role of mTOR inhibitors in epilepsy treatment

Pharmacological Reports

Volumn 67, Issue 3, 2015, Pages 636-646

  Sadowski, Krzysztof ^a   Kotulska Jóźwiak, Katarzyna ^b   Jóźwiak, Sergiusz ^b  

^a Living with Parkinson Disease Foundation   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Epilepsy; Epileptogenesis; mTOR inhibitors; Rapamycin; Tuberous sclerosis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ANTICONVULSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CORTICAL DYSPLASIA; DRUG TARGETING; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; INFANTILE SPASM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TEMPORAL LOBE EPILEPSY; TRAUMATIC BRAIN INJURY; TUBEROUS SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; BRAIN; EPILEPSY; HUMANS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84925834974     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.12.017     Document Type: Review

References (132)

1. WHO. Epilepsy. http://www.who.int/mediacentre/factsheets/fs999/en/.
2. A. Pitkänen, and K. Łukasiuk Mechanisms of epileptogenesis and potential treatment targets Lancet Neurol 10 2 2011 173 186
3. N.D. Child, and E.E. Benarroch mTOR: its role in the nervous system and involvement in neurologic disease Neurology 83 17 2014 1562 1572
4. D.S. Sarbassov, S.M. Ali, and D.M. Sabatini Growing roles for the mTOR pathway Curr Opin Cell Biol 17 6 2005 596 603
5. C. Vezina, A. Kudelski, and S.R. Sehgal Rapamycin (AY 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J Antibiot 28 10 1975 721 726
6. S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 4 2005 525 537
7. E.J. Brown, M.W. Albers, T.B. Shin, K. Ichikawa, C.T. Keith, and W.S. Lane A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 6483 1994 756 758
8. D.M. Sabatini, H. Erdjument-Bromage, M. Lui, P. Tempst, and S.H. Snyder RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs Cell 78 1 1994 35 43
9. J. Kunz, R. Henriquez, U. Schneider, M. Deuter-Reinhard, N.R. Movva, and M.N. Hall Target of rapamycin in yeast: TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression Cell 73 3 1993 585 596
10. J. Heitman, N.R. Movva, and M.N. Hall Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 5022 1991 905 909
11. T.A. Huffman, I. Mothe-Satney, and J.C. Lawrence Jr. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin PNAS 99 2 2002 1047 1052
12. J.R. Mc Mullen, M.C. Sherwood, O. Tarnavski, L. Zhang, A.L. Dorfman, and T. Shioi Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload Circulation 109 24 2004 3050 3055
13. B. Ravikumar, C. Vacher, Z. Berger, J.E. Davies, S. Luo, and L.G. Oroz Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease Nat Genet 36 6 2004 585 595
14. C.T. Keith, and S.L. Schreiber PIK-related kinases: DNA repair, recombination and cell cycle checkpoints Science 270 5233 1995 50 51
15. X.F. Zheng, D. Florentino, J. Chen, G.R. Crabtree, and S.L. Schreiber TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin Cell 82 1 1995 121 130
16. J. Choi, J. Chen, S.L. Schreiber, and J. Clardy Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273 5272 1996 239 242
17. M.A. Andrade, and P. Bork HEAT repeats in the Huntington's disease protein Nat Genet 11 2 1995 115 116
18. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, and H. Erdjument-Bromage mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2 2002 163 175
19. R.T. Abraham Identification of TOR signaling complexes: more TORC for the cell growth engine Cell 111 1 2002 9 12
20. M.A. Frias, C.C. Thoreen, J.D. Jaffe, W. Schroder, T. Sculley, and S.A. Carr mSin1 is necessary for Akt/PKB phosphorylation: and its isoforms define three distinct mTORC2s Curr Biol 16 18 2006 1865 1870
21. V. Zinzalla, D. Stracka, W. Oppliger, and M.N. Hall Activation of mTORC2 by association with the ribosome Cell 144 5 2011 757 768
22. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 5712 2005 1098 1101
23. E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M.A. Ruegg, and A. Hall Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 6 11 2004 1122 1128
24. K. Shimada, I. Filipuzzi, M. Stahl, S.B. Helliwell, C. Studer, and D. Hoepfner TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks Mol Cell 51 6 2013 829 839
25. D.D. Sarbassov, S.M. Ali, S. Sengupta, J.H. Sheen, P.P. Hsu, and A.F. Bagley Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 2 2006 159 168
26. K. Inoki, M.N. Corradetti, and K.L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 1 2005 19 24
27. C.A. Hoeffer, and E. Klann mTOR signaling: at the crossroads of plasticity, memory and disease Trends Neurosci 33 2 2010 67 75
28. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.L. Guan TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 9 2002 648 657
29. M.L. Sulis, and R. Parsons PTEN: from pathology to biology Trends Cell Biol 13 9 2003 478 483
30. E.G. Puffenberger, K.A. Strauss, K.E. Ramsey, D.W. Craig, D.A. Stephan, and D.L. Robinson Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5 Brain 130 7 2007 1929 1941
31. A.R. Tee, B.D. Manning, P.P. Roux, L.C. Cantley, and J. Blenis Tuberous sclerosis complex gene products: tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb Curr Biol 13 15 2003 1259 1268
32. K. Inoki, H. Ouyang, Y. Li, and K.L. Guan Signaling by target of rapamycin proteins in cell growth control Microbiol Mol Biol Rev 69 1 2005 79 100
33. K. Inoki, T. Zhu, and K.L. Guan TSC2 mediates cellular energy response to control cell growth and survival Cell 115 5 2003 577 590
34. J. Brugarolas, K. Lei, R.L. Hurley, B.D. Manning, J.H. Reiling, and E. Hafen Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex Genes Dev 18 23 2004 2893 2904
35. Z. Feng, H. Zhang, A.J. Levine, and S. Jin The coordinate regulation of the p53 and mTOR pathways in cells PNAS 102 23 2005 8204 8209
36. X. Gan, J. Wang, B. Su, and D. Wu Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 286 13 2011 10998 11002
37. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2 2012 274 293
38. R.J. White, and A.D. Sharrocks Coordinated control of the gene expression machinery Trends Genet 26 5 2010 214 220
39. C.H. Kwon, X. Zhu, J. Zhang, and S.J. Baker mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo PNAS 100 22 2003 12923 12928
40. J. Chung, C.J. Kuo, G.R. Crabtree, and J. Blenis Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases Cell 69 7 1992 1227 1236
41. P.E. Burnett, R.K. Barrow, N.A. Cohen, S.H. Snyder, and D.M. Sabatini RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 PNAS 95 4 1998 1432 1437
42. D.C. Fingar, S. Salama, C. Tsou, E. Harlow, and J. Blenis Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E Genes Dev 16 12 2002 1472 1487
43. C.L. Pelletier, L.B. Maggi Jr., S.N. Brady, D.K. Scheidenhelm, D.H. Gutmann, and J.D. Weber TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation Cancer Res 67 4 2007 1609 1617
44. J. Jóźwiak, K. Kotulska, W. Grajkowska, S. Jóźwiak, W. Zalewski, and M. Ołdak Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas Brain Dev 29 5 2007 273 280
45. S. Carloni, G. Buonocore, and W. Balduini Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury Neurobiol Dis 32 3 2008 329 339
46. A.W. Thomson, H.R. Turnquist, and G. Raimondi Immunoregulatory functions of mTOR inhibition Nat Rev Immunol 9 5 2009 324 337
47. E. Russo, F. Andreozzi, R. Iuliano, V. Dattilo, T. Procopio, and G. Fiume Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release Brain Behav Immun 2014 10.1016/j.bbi.2014.06.016
48. L. Xie, F. Sun, J. Wang, X. Mao, L. Xie, and S.H. Yang mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia J Immunol 192 12 2014 6009 9019
49. R.T. Abraham, J.J. Gibbons, and E.I. Graziani Chemistry and pharmacology of rapamycin and its derivatives Enzymes 27 17 2010 329 366
50. Y.Y. Zaytseva, J.D. Valentino, P. Gulhati, and B.M. Evers MTOR inhibitors in cancer therapy Cancer Lett 319 1 2012 1 7
51. L.R. Pearce, G.R. Alton, D.T. Richter, J.C. Kath, L. Lingardo, and J. Chapman Characterization of PF-4708671: a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1) Biochem J 431 2 2010 245 255
52. J. Jóźwiak, S. Jóźwiak, and P. Włodarski Possible mechanisms of disease development in tuberous sclerosis Lancet Oncol 9 1 2008 73 79
53. D.J. Kwiatkowski, and B.D. Manning Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways Hum Mol Genet 14 Suppl. 2 2005 251 258
54. P. Curatolo, R. Bombardieri, and S. Jóźwiak Tuberous sclerosis Lancet 372 9639 2008 657 668
55. C.J. Chu-Shore, P. Major, S. Camposano, D. Muzykewicz, and E.A. Thiele The natural history of epilepsy in tuberous sclerosis complex Epilepsia 51 7 2010 1236 1241
56. J.R. Yates Tuberous sclerosis Eur J Hum Genet 14 10 2006 1065 1073
57. A. Humphrey, C. MacLean, G.B. Ploubidis, Y. Granader, M. Clifford, and M. Haslop Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis Epilepsia 55 1 2014 108 116
58. L. Lee, P. Sudentas, B. Donohue, K. Asrican, A. Worku, and V. Walker Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models Genes Chromosomes Cancer 42 3 2005 213 227
59. J. Jaworski, S. Spangler, D.P. Seeburg, C.C. Hoogenraad, and M. Sheng Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway J Neurosci 25 49 2005 11300 11312
60. K.F. Raab-Graham, P.C. Haddick, Y.N. Jan, and L.Y. Jan Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites Science 314 5796 2006 144 148
61. L. Meikle, K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, and M. Sahin Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function J Neurosci 28 21 2008 5422 5432
62. L.H. Zeng, L. Xu, D.H. Gutmann, and M. Wong Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex Ann Neurol 63 4 2008 444 453
63. H. Onda, A. Lueck, P.W. Marks, H.B. Warren, and D.J. Kwiatkowski Tsc2 mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background J Clin Investig 104 6 1999 687 695
64. C. von der Brelie, R. Waltereit, L. Zhang, H. Beck, and T. Kirschstein Impaired synaptic plasticity in a rat model of tuberous sclerosis Eur J Neurosci 23 3 2006 686 692
65. D. Ehninger, S. Han, C. Shilyansky, Y. Zhou, W. Li, and D.J. Kwiatkowski Reversal of learning deficits in a Tsc2 mouse model of tuberous sclerosis Nat Med 14 8 2008 843 848
66. D.M. Talos, H. Sun, X. Zhou, E.C. Fitzgerald, M.C. Jackson, and P.M. Klein The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway PLoS ONE 7 5 2012 e35885
67. J. Goto, D.M. Talos, P. Klein, W. Qin, Y.I. Chekaluk, and S. Anderl Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex PNAS 108 45 2011 1070 1079
68. S. Anderl, M. Freeland, D.J. Kwiatkowski, and J. Goto Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex Hum Mol Genet 20 23 2011 4597 4604
69. M. Cambiaghi, M. Cursi, L. Magri, V. Castoldi, G. Comi, and F. Minicucci Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex Neuropharmacology 67 2013 1 7
70. S.W. Way, N.S. Rozas, H.C. Wu, J. McKenna 3rd., R.M. Reith, and S.S. Hashmi The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex Hum Mol Genet 21 14 2012 3226 3236
71. J.T. Lerner, N. Salamon, J.S. Hauptman, T.R. Velasco, M. Hemb, and J.Y. Wu Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience Epilepsia 50 6 2009 1310 1335
72. I. Blümcke, M. Thom, E. Aronica, D.D. Armstrong, H.V. Vinters, and A. Palmini The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission Epilepsia 52 1 2011 158 174
73. M. Baybis, J. Yu, A. Lee, J.A. Golden, H. Weiner, and G. McKhann 2nd. mTOR cascade activation distinguishes tubers from focal cortical dysplasia Ann Neurol 56 4 2004 478 487
74. A.J. Becker, H. Urbach, B. Scheffler, T. Baden, S. Normann, and R. Lahl Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis Ann Neurol 52 1 2002 29 37
75. A. Schönberger, P. Niehusmann, H. Urbach, M. Majores, A. Grote, and H. Holthausen Increased frequency of distinct TSC2 allelic variants in focal cortical dysplasias with balloon cells and mineralization Neuropathology 29 5 2009 559 565
76. C. Gumbinger, C.B. Rohsbach, H. Schulze-Bonhage, R. Korinthenberg, J. Zentner, and M. Häffner Focal cortical dysplasia: a genotype-phenotype analysis of polymorphisms and mutations in the TSC genes Epilepsia 50 6 2009 1396 1408
77. W. Grajkowska, K. Kotulska, E. Matyja, M. Larysz-Brysz, M. Mandera, and M. Roszkowski Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type Folia Neuropathol 46 1 2008 43 48
78. C. Cepeda, V.M. Andrè, I. Yamazaki, J.S. Hauptman, J.Y. Chen, and H.V. Vinters Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II Epilepsia 51 Suppl. 3 2010 166 170
79. J. Chen, V. Tsai, W.E. Parker, E. Aronica, M. Baybis, and P.B. Crino Detection of human papillomavirus in human focal cortical dysplasia type IIB Ann Neurol 72 6 2012 881 892
80. J. Liu, C. Reeves, Z. Michalak, A. Coppola, B. Diehl, and S.M. Sisodiya Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies Acta Neuropathol Commun 2 2014 71 10.1186/2051-5960-2-71
81. H. Bastos, P.F. da Silva, M.A. de Albuquerque, A. Mattos, R.S. Riesgo, and L. Ohlweiler Proteus syndrome associated with hemimegalencephaly and Ohtahara syndrome: report of two cases Seizure 17 4 2008 378 382
82. C.H. Kwon, X. Zhu, J. Zhang, and S.J. Baker mTOR is required for hypertrophy of Pten-deficient neuronal soma in vivo PNAS 100 22 2003 12923 12928
83. J. Zhou, J. Blundell, S. Ogawa, C.H. Kwon, W. Zhang, and C. Sinton Pharmacological inhibition of mTORC1 suppresses anatomical: cellular, and behavioral abnormalities in neural-specific Pten knock-out mice J Neurosci 29 6 2009 1773 1783
84. W.E. Parker, K.A. Orlova, W.H. Parker, J.F. Birnbaum, V.P. Krymskaya, and D.A. Goncharov Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder Sci Transl Med 5 182 2013 182ra53 10.1126/scitranslmed.3005271
85. P.B. Crino Focal brain malformations: a spectrum of disorders along the mTOR cascade Novartis Found Symp 288 2007 260 272
86. P.B. Crino mTOR: a pathogenic signaling pathway in developmental brain malformations Trends Mol Med 17 12 2011 734 742
87. S. Banerjee, N.R. Crouse, R.J. Emnett, S.M. Gianino, and D.H. Gutmann Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner PNAS 108 38 2011 15996 16001
88. F. Shirazi, C. Cohen, L. Fried, and J.L. Arbiser Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo Lymphat Res Biol 5 4 2007 233 236
89. J.J. Chern, A.J. Patel, A. Jea, D.J. Curry, and Y.G. Comair Surgical outcome for focal cortical dysplasia: an analysis of recent surgical series J Neurosurg Pediatr 6 5 2010 452 458
90. D. Madhavan, S. Schaffer, A. Yankovsky, A. Arzimanoglou, F. Renaldo, and C.M. Zaroff Surgical outcome in tuberous sclerosis complex: a multicenter survey Epilepsia 48 8 2007 1625 1628
91. P. Major, S. Rakowski, M.V. Simon, M.L. Cheng, E. Eskandar, and J. Baron Are cortical tubers epileptogenic? Evidence from electrocorticography Epilepsia 50 1 2009 147 154
92. C.L. Lasarge, and S.C. Danzer Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation Front Mol Neurosci 7 18 2014 10.3389/fnmol.2014.00018.eCollection 2014
93. J.M. Pellock, R. Hrachovy, S. Shinnar, T.Z. Baram, D. Bettis, and D.J. Dlugos Infantile spasms: a U.S. consensus report Epilepsia 51 10 2010 2175 2189
94. P. Pavone, P. Striano, R. Falsaperla, L. Pavone, and M. Ruggieri Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013 Brain Dev 36 9 2013 739 751
95. E. Raffo, A. Coppola, T. Ono, S.W. Briggs, and A.S. Galanopoulou A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol Dis 43 2 2011 322 329
96. T. Chachua, M.S. Yum, J. Velišková, and L. Velišek Validation of the rat model of cryptogenic infantile spasms Epilepsia 52 9 2011 1666 1677
97. C.E. Stafstrom, and G.L. Holmes Infantile spasms: criteria for an animal model Int Rev Neurobiol 49 2002 391 411
98. O. Dulac, C. Soufflet, C. Chiron, and A. Kaminska What is West syndrome Int Rev Neurobiol 49 2002 1 22
99. A.S. Galanopoulou Basic mechanisms of catastrophic epilepsy - overview from animal models Brain Dev 35 8 2013 748 756
100. R. Riikonen Recent advances in the pharmacotherapy of infantile spasms CNS Drugs 28 4 2014 279 290
101. X. Huang, H. Zhang, J. Yang, J. Wu, J. McMahon, and Y. Lin Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy Neurobiol Dis 40 1 2010 193 199
102. P.S. Buckmaster, E.A. Ingram, and X. Wen Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy J Neurosci 29 25 2009 8259 8269
103. M. Macias, M. Błażejczyk, P. Kaźmierska, B. Caban, A. Skałecka, and B. Tarkowski Spatiotemporal characterization of mTOR kinase activity following kainic acid induced status epilepticus and analysis of rat brain response to chronic rapamycin treatment PLOS ONE 8 5 2013 e64455
104. A.L. Brewster, J.N. Lugo, V.V. Patil, W.L. Lee, Y. Qian, and F. Vanegas Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage PLOS ONE 8 3 2013 e57808
105. E.A. van Vliet, G. Forte, L. Holtman, J.C. den Burger, A. Sinjewel, and H.E. de Vries Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation Epilepsia 53 7 2012 1254 1263
106. L.H. Zeng, N.R. Rensing, and M. Wong The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy J Neurosci 29 21 2009 6964 6972
107. P.S. Buckmaster, and F.H. Lew Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy J Neurosci 31 6 2011 2337 2347
108. A. ͆liwa, G. Plucińska, J. Bednarczyk, and K. Łukasiuk Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy Neurosci Lett 509 2 2012 105 109
109. S. Erlich, A. Aleksandrovich, E. Sholami, and R. Pinkas-Kramarski Rapamycin is a neuroprotective treatment for traumatic brain injury Neurobiol Dis 26 1 2007 86 93
110. J. Park, J. Zhang, J. Qiu, X. Zhu, A. Degterev, and E.H. Lo Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice J Cereb Blood Flow Metab 32 2 2012 330 340
111. D.M. Talos Rapamycin attenuates the increases in seizure susceptibility and neuronal excitability following neonatal seizures in rat Epilepsy Curr 11 Suppl. 1 2011
112. E. Russo, R. Citraro, G. Donato, C. Camastra, R. Iuliano, and S. Cuzzocrea mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy Neuropharmacology 69 2013 25 36
113. E. Russo, P. Follesa, R. Citraro, C. Camastra, A. Donato, and D. Isola The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model Neurol Sci 35 11 2014 1793 1799
114. D. González, C.D. García, M. Azócar, S. Waller, A. Alonso, and G. Ariceta Growth of kidney-transplanted pediatric patients treated with sirolimus Pediatr Nephrol 26 6 2011 961 966
115. G.A. Rangel, and G. Ariceta Growth failure associated with sirolimus: case report Pediatr Nephrol 24 10 2009 2047 2050
116. K. Kotulska, D. Chmielewski, J. Borkowska, E. Jurkiewicz, D. Kuczyński, and T. Kmieć Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex Eur J Paediatr Neurol 17 5 2013 479 485
117. P. Curatolo, S. Jóźwiak, and R. Nabbout Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations Eur J Paediatr Neurol 16 6 2012 582 586
118. B. Zhang, S.S. McDaniel, N.R. Rensing, and M. Wong Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex PLOS ONE 8 2 2013 e57445
119. D.N. Franz, J. Leonard, C. Tudor, G. Chuck, M. Care, and G. Sethuraman Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann Neurol 59 3 2006 490 498
120. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, and P. Mangeshkar Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 19 2010 1801 1811
121. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, and R. Kuperman Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 9861 2013 125 132
122. J.J. Bissler, J.C. Kingswood, E. Radzikowska, B.A. Zonnenberg, M. Frost, and E. Belousova Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial Lancet 381 9869 2013 817 824
123. S. Jóźwiak, R. Nabbout, and P. Curatolo Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations Eur J Paediatr Neurol 17 4 2013 348 352
124. J. Muncy, I.J. Butler, and M.K. Koenig Rapamycin reduces seizures frequency in tuberous sclerosis complex J Child Neurol 24 4 2009 477
125. M. Perek-Polnik, S. Jóźwiak, E. Jurkiewicz, D. Perek, and K. Kotulska Effective everolimus treatment of inoperable: life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex Eur J Paediatr Neurol 16 1 2012 83 85
126. D.A. Krueger Everolimus treatment of refractory epilepsy in tuberous sclerosis complex Ann Neurol 74 5 2013 679 687
127. D.A. Krueger, M.M. Care, K. Agricola, C. Tudor, M. Mays, and D.N. Franz Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma Neurology 80 6 2013 574 580
128. G. Wiegand, T.W. May, P. Ostertag, R. Boor, U. Stephani, and D.N. Franz Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 17 6 2013 631 638
129. M. Cardamone, D. Flanagan, D. Mowat, S.E. Kennedy, M. Chopra, and J.A. Lawson Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex J Pediatr 164 5 2014 1195 1200
130. A. Wiemer-Kruel, H. Woerle, K. Strobl, and T. Bast Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report Neuropediatrics 45 2 2014 129 131
131. A.S. Galanopoulou, P.S. Buckmaster, K.J. Staley, S.L. Moshe, E. Perucca, and J. Engel Jr. Identification of new epilepsy treatments: issues in preclinical methodology Epilepsia 53 3 2012 571 582
132. S. Jóźwiak, K. Kotulska, D. Domańska-Pakieła, B. Łojszczyk, M. Syczewska, and D. Chmielewski Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex Eur J Paediatr Neurol 15 5 2011 424 431